Key Highlights
- Diluted loss per share was USD 5.13 against an estimate of a USD 6.60 loss.
- Net income was USD 17.84 million, compared with a net loss of USD 10.12 million.
- Loss from operations was USD 4.37 million, compared with USD 5.72 million.
- Cash and cash equivalents were USD 3.10 million at September 30, 2026.
Adagio Medical Holdings (NASDAQ:ADGM) reported Net Income of USD 17.84 million for the third quarter of 2026, compared with a net loss of USD 10.12 million in the third quarter of 2025. The basic net income per share was USD 2.40, and the diluted net loss per share was USD 5.13, compared with a loss of USD 19.73, against an estimate of a USD 6.60 loss.
The company reported no Revenue in either period. Per share amounts reflect the Reverse Stock Split effected on November 6, 2026.
Operating Results
Research and development expense was USD 1.80 million, compared with USD 2.77 million, and selling, general and administrative expense was USD 2.57 million, compared with USD 2.92 million. The filing states that the decrease in selling, general and administrative expense was primarily due to lower professional services and regulatory reporting expenses, partially offset by higher Payroll and personnel expenses. Total cost of revenue and operating expenses were USD 4.37 million, compared with USD 5.72 million, which equals the loss from operations.
Other Income and Expense
The convertible notes Fair Value adjustment was a gain of USD 22.95 million, compared with a loss of USD 3.51 million. Interest expense was USD 0.84 million, compared with USD 0.75 million, and interest income was USD 0.04 million, compared with USD 0.08 million. Total other income, net, was USD 22.21 million, compared with total other expense, net, of USD 4.40 million.
For the nine months ended September 30, 2026, net income was USD 4.13 million, compared with a net loss of USD 21.78 million. The loss from operations was USD 14.51 million, compared with USD 17.92 million, and the diluted net loss per share was USD 17.13, compared with USD 42.48.
Balance Sheet and Liquidity
Cash and cash equivalents were USD 3.10 million at September 30, 2026, compared with USD 17.11 million at December 31, 2025. Inventory, net, was USD 2.72 million, compared with USD 1.67 million, and total Assets were USD 29.86 million, compared with USD 43.25 million. Convertible notes payable, net, were USD 2.01 million, compared with USD 21.04 million, and total liabilities were USD 11.50 million, compared with USD 30.85 million. Total stockholders' Equity was USD 18.36 million, compared with USD 12.40 million.
The filing states that net cash used in Operating Activities was USD 14.0 million for the nine months, and that the company does not believe its existing cash and cash equivalents are sufficient to fund its operating and Capital Expenditure requirements for at least 12 months from the issuance date of the financial statements. The filing states that these factors raise substantial doubt about its ability to continue as a going concern.
Adagio Medical Holdings Q3 2026 Earnings: Key Takeaways
Adagio Medical Holdings reported third quarter 2026 net income of USD 17.84 million and a loss from operations of USD 4.37 million. Cash and cash equivalents were USD 3.10 million at September 30, 2026.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...